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Previous studies on human T lymphocytes have shown that the
degranulation marker CD107a can be used to deﬁne T cells, which
show tumor speciﬁc cytolysis. To determine whether CD107a can
be used in the murine setting as a marker for cytolysis, we ﬁrst
tested the degranulation activity on splenocytes from C57BL/6
(H-2b), FVB (H-2q) or Balb/c (H-2d) against Balb/c splenocytes.
Results from the mixed lymphocyte cytolytic assays (MLCA) and
cytolytic assays [51Cr] showed a high degree of correlation with
CD107a expression by FACS analyses. We next analyzed the
degranulation activity of murine CIK cells by evaluating their
capacity to mobilize CD107a to the cell membrane as a parameter
of tumor speciﬁc cytolysis. CIK cells showed a high cytolytic
capacity in 51Cr assays when directed against syngeneic and allo-
geneic tumor cell lines (A20, P3X63, EL4, Yac-1 and P815). CIK
cytotoxicity correlated with CD107a expression by FACS analyses.
Immunoﬂuorescence microscopy could conﬁrm the existence of
CD107a positive cytolytic granules in CIK cells from tumor cyto-
toxic assays. Using in vivo Bioluminescence Imaging (BLI) we
characterized the migration pattern of CIK cells derived from a
luciferase expressing transgenic mouse in tumor-bearing mice as
compared to healthy controls. Furthermore, Balb/c mice bearing a
sub-cutaneous A20 lymphoma, revealed tumor-speciﬁc homing of
CIK cells and reduction of the tumor size within 3 days after i.v.
injection. To identify tumor-speciﬁc CIK in vivo we are currently
combining imaging techniques with CD107a degranulation anal-
ysis. These data will help to elucidate the complex cellular inter-
action mounting a graft-versus-tumor response, which depends on
an effective combination of efﬁcient trafﬁcking, recognition and
elimination of the tumor cells.
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METHOTREXATE ALTERS HEMATOPOIETIC RECOVERY AND ENGRAFT-
MENT KINETICS WHEN ADDED TO CYCLOSPORINE FOR ACUTE GVHD
PROPHYLAXIS AFTER REDUCED-INTENSITY STEM CELL TRANSPLAN-
TATION
Dean, R.M.; Fowler, D.H.; Odom, J.; Castro, K.M.; Kasten-Sportes, C.;
Wilson, W.H.; Gress, R.E.; Bishop, M.R. Center for Cancer Research,
National Cancer Institute, Bethesda, MD.
Methotrexate (MTX) is a standard drug for graft-versus-host
disease (GVHD) prophylaxis, but its effects on hematopoietic re-
covery and donor engraftment in the setting of reduced-intensity
stem cell transplantation (RIST) are not well described. We com-
pared these parameters and acute GVHD in patients with hema-
tologic malignancies undergoing RIST on 2 consecutive clinical
trials using identical reduced-intensity conditioning (ﬂudarabine
and cyclophosphamide). Group 1 included 50 patients receiving
cyclosporine (CSA) alone for GVHD prophylaxis after RIST.
Group 2 included 24 patients receiving CSA MTX (5 mg/m2 on
days 1, 3, 6, 11) for GVHD prophylaxis. The groups were
similar with respect to host immune status before RIST, age, and
allograft dose of CD34 and CD3 cells. All patients in each group
received salvage therapy with etoposide, prednisone, vincristine,
cyclophosphamide, and doxorubicin plus ﬂudarabine (EPOCH-F)
prior to RIST. Fourteen patients in the CSA/MTX group also
received rituximab with EPOCH-F. Hematopoietic recovery was
delayed in the CSA/MTX group, with median neutrophil recovery
(500/L) and platelet recovery (100K/L) occurring 3 and 6.5
days later, respectively, than in the CSA group. Donor engraftment
was rapid and complete for most patients in each group (median
total mononuclear cell chimerism 100% at day 28 for both
groups), and no patient experienced graft rejection. However, full
donor chimerism (95%) was less common for CSA/MTX (75%
at day28, 71% at day100) than for CSA (90% at day28, 97%
at day 100). Adding MTX to CSA decreased the incidence and
severity of acute GVHD. Grade 2–4 acute GVHD occurred in
33/50 (66%) CSA patients, versus 9/24 (38%) CSA/MTX patients.
Grade 3–4 GVHD affected 17/50 (34%) CSA patients, including
6 with grade 4 GVHD and 8 with steroid-refractory disease. In
contrast, only 5/24 (21%) of CSA/MTX patients had grade 3
GVHD, while none had grade 4 or steroid-refractory GVHD. No
treatment-related deaths occurred in the CSA/MTX group, but 14
CSA patients died of treatment-related complications. Thus, the
addition of MTX to CSA markedly attenuates the GVH response
post RIST, slowing donor engraftment and delaying hematopoietic
recovery. These data illustrate the sensitivity of engraftment kinet-
ics to the intensity of GVHD prophylaxis following RIST. Further
studies should determine if CSA/MTX will be associated with an
increased risk of disease progression after RIST.
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GRADE 2–4 ACUTE GRAFT-VERSUS-HOST DISEASE AND EXTENSIVE
CHRONIC GRAFT VERSUS HOST DISEASE ARE ASSOCIATED WITH SIG-
NIFICANTLY DECREASED SURVIVAL FOLLOWING REDUCED INTENSITY
ALLOGENEIC STEM CELL TRANSPLANTATION
Chan, G.W.1; Klein, A.K.1; Sprague, K.A.1; Miller, K.B.2; Foss, F.M.1
1. Tufts-New England Medical Center, Boston, MA; 2. Beth Israel
Deaconess Medical Center, Boston, MA.
Grade 2–4 acute graft-versus-host-disease (aGVHD) and extensive
chronic GVHD (cGVHD) are associated with decreased overall sur-
vival (OS) following conventional allogeneic stem cell transplantation
but their impact on reduced intensity transplantation remains contro-
versial. We evaluated the impact of GVHD on survival in 112 high-
risk patients, median age 50 years (range 18–70), with AML (n29),
MDS (n19), CML (n9), CLL (n5), ALL (n3), HD (n10),
NHL (n16), MM (n9), MMM (n7), PNH (n2), or renal cell
carcinoma (n3), who underwent a reduced intensity preparative
regimen of extracorporeal photopheresis day 7, 6, pentostatin 8
mg/m2 by continuous intravenous infusion day 5 through 4, and
total body irradiation in three 200 cGy fractions day3,2, followed
by allogeneic bone marrow stem cell infusion from 6/6 HLAmatched
related (n70), 5/6 HLA matched related (n10), or matched unre-
lated (n32) donors. Thirty patients had prior autologous stem cell
transplantation and 5 patients had prior conventional allogeneic stem
cell transplantation. Full donor chimerism occurred in 89% of pa-
tients. Day 100 transplant related mortality (TRM) was 20%. The
disease relapse rate was 22%. Grade 2, 3 or 4 aGVHD occurred in
7%, 6%, and 6% of patients respectively. The one-year OS by
aGVHD grade was 70% for grade 0, 69% for grade 1, 29% for grade
2, 17% for grade 3, and 0% for grade 4. Grade 2–4 aGVHD was
associated with higher day 100 TRM (37% vs 14%: p0.03) and
decreased median OS (5 months vs “not reached”: p0.001). Median
OS was lower among patients with grade 2–4 aGVHD as compared
to patients with grade 0–1 aGVHD in matched related donor trans-
plants (5 months vs “not reached”: p0.002) and in mismatched
related or matched unrelated donor transplants (6 months vs 35
months: p0.0004). Patients with grade 2 or grade 3–4 aGVHD had
similar median OS (6 months vs 3 months: p0.24). Patients with
limited or no cGVHD had similar one-year OS (90% vs 79%) but
patients with extensive cGVHD had a signiﬁcantly worse one-year
OS (56% vs 82% p0.0007). In conclusion, high-risk patients who
undergo reduced intensity transplantation and develop grade 2–4
aGVHD or extensive cGVHD tolerate GVHD poorly, leading to
signiﬁcantly higher TRM and decreased overall survival. Patients with
grade 2 aGVHD or grade 3–4 aGVHD have similarly poor OS. To
improve survival, reduced intensity transplantation regimens that de-
crease the incidence of grade 2–4 aGVHDor extensive cGVHDneed
to be developed.
HISTOCOMPATIBILITY/ALTERNATIVE
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SIGNIFICANCE OF ONE HUMAN LEUKOCYTE ANTIGEN MISMATCH ON
OUTCOME OF NON-MYELOABLATIVE ALLOGENEIC STEM CELL TRANS-
PLANTATION FROM RELATED DONORS USING THE MEXICAN SCHED-
ULE
Ruiz-Arguelles, G.J.1,2; Lopez-Martinez, B.2; Manzano, C.1; Gomez-
Rangel, J.D.1; Lobato-Mendizabal, E.1 1. Centro de Hematologia y
Medicina Interna, Puebla, Mexico; 2. Laboratorios Clinicos de Puebla,
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